The study was renewed in 1994 and again in 1998 to continue follow-up for an additional four years. Follow-up continued of these adolescents and young adults who were 13 to 20 years old in 1998. The purpose was to index early markers of preclinical disease including resting blood pressure, left ventricular mass, and several new measures including plasma endothelin-1 (ET-1) and endothelium dependent arterial dilation (EDAD).